Intersect ENT, Inc. (NASDAQ:XENT) Insider Lisa D. Earnhardt Sells 20,000 Shares of Stock

Intersect ENT, Inc. (NASDAQ:XENT) insider Lisa D. Earnhardt sold 20,000 shares of the stock in a transaction on Monday, July 17th. The shares were sold at an average price of $29.03, for a total value of $580,600.00. Following the completion of the transaction, the insider now directly owns 580,868 shares in the company, valued at approximately $16,862,598.04. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Intersect ENT, Inc. (NASDAQ:XENT) opened at 29.05 on Wednesday. The stock’s market cap is $835.83 million. The company’s 50 day moving average price is $27.03 and its 200-day moving average price is $19.14. Intersect ENT, Inc. has a 12-month low of $7.65 and a 12-month high of $29.26.

Intersect ENT (NASDAQ:XENT) last announced its quarterly earnings data on Tuesday, May 2nd. The medical equipment provider reported ($0.23) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.25) by $0.02. Intersect ENT had a negative net margin of 28.71% and a negative return on equity of 20.49%. The business had revenue of $20.47 million during the quarter, compared to the consensus estimate of $19.39 million. On average, analysts forecast that Intersect ENT, Inc. will post ($0.74) EPS for the current year.

WARNING: “Intersect ENT, Inc. (NASDAQ:XENT) Insider Lisa D. Earnhardt Sells 20,000 Shares of Stock” was posted by BBNS and is the property of of BBNS. If you are reading this report on another domain, it was copied illegally and reposted in violation of United States & international copyright and trademark legislation. The original version of this report can be viewed at https://baseballnewssource.com/markets/intersect-ent-inc-nasdaqxent-insider-lisa-d-earnhardt-sells-20000-shares-of-stock/1229523.html.

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Teachers Retirement System of The State of Kentucky boosted its position in Intersect ENT by 35.9% in the first quarter. Teachers Retirement System of The State of Kentucky now owns 37,663 shares of the medical equipment provider’s stock valued at $646,000 after buying an additional 9,957 shares during the period. Iguana Healthcare Management LLC boosted its position in Intersect ENT by 33.3% in the first quarter. Iguana Healthcare Management LLC now owns 100,000 shares of the medical equipment provider’s stock valued at $1,715,000 after buying an additional 25,000 shares during the period. Paulson & CO. Inc. purchased a new position in Intersect ENT during the first quarter valued at approximately $10,978,000. Bank of America Corp DE boosted its position in Intersect ENT by 3.9% in the first quarter. Bank of America Corp DE now owns 103,275 shares of the medical equipment provider’s stock valued at $1,771,000 after buying an additional 3,892 shares during the period. Finally, Schwab Charles Investment Management Inc. boosted its position in Intersect ENT by 6.1% in the first quarter. Schwab Charles Investment Management Inc. now owns 120,838 shares of the medical equipment provider’s stock valued at $2,073,000 after buying an additional 6,963 shares during the period. Hedge funds and other institutional investors own 76.12% of the company’s stock.

Several equities analysts recently commented on XENT shares. Zacks Investment Research lowered Intersect ENT from a “hold” rating to a “sell” rating in a report on Wednesday, July 5th. ValuEngine raised Intersect ENT from a “sell” rating to a “hold” rating in a report on Friday, June 2nd. William Blair reissued an “outperform” rating on shares of Intersect ENT in a report on Wednesday, May 10th. Northland Securities lowered Intersect ENT from an “outperform” rating to a “market perform” rating in a report on Wednesday, May 31st. Finally, Canaccord Genuity reissued a “buy” rating on shares of Intersect ENT in a report on Wednesday, May 3rd. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and seven have assigned a buy rating to the stock. Intersect ENT currently has a consensus rating of “Buy” and an average target price of $18.60.

Intersect ENT Company Profile

Intersect ENT, Inc is a commercial-stage drug-device company. The Company develops drugs for patients with ear, nose and throat (ENT) conditions. The Company has developed a drug releasing bioabsorbable implant technology that enables targeted and sustained release of therapeutic agents. This targeted drug delivery technology is designed to allow ENT physicians to manage patient care.

Insider Buying and Selling by Quarter for Intersect ENT (NASDAQ:XENT)

Receive News & Ratings for Intersect ENT Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intersect ENT Inc. and related companies with our FREE daily email newsletter.

 


Latest News

Todd Frazier Traded to Yankees for Blake Rutherford and Others
Todd Frazier Traded to Yankees for Blake Rutherford and Others
Tigers Would Include Cash in Verlander Deal and Other MLB Trade Rumors
Tigers Would Include Cash in Verlander Deal and Other MLB Trade Rumors
Todd Frazier Trade to Boston Appears to Be Decided
Todd Frazier Trade to Boston Appears to Be Decided
Chicago White Sox Continue Rebuild Without Jose Quintana
Chicago White Sox Continue Rebuild Without Jose Quintana
Mike Trout Returns from Injury With Single and Stole Base
Mike Trout Returns from Injury With Single and Stole Base
Chicago Cubs Strengthen Rotation Through Trade for Jose Quintana
Chicago Cubs Strengthen Rotation Through Trade for Jose Quintana


Leave a Reply

 
© 2006-2017 BBNS.